TrialFrontiers in immunology2023

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.

Yunyan Mo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.